Form 4: Protara Therapeutics CEO Jesse Shefferman Acquires Shares and Stock Options
SEC Form 4 Filing
CEO Jesse Shefferman of Protara Therapeutics acquired 65,000 shares of common stock and stock options for 387,000 shares on January 24, 2025.
Summary
- On January 24, 2025, Jesse Shefferman, CEO and President of Protara Therapeutics, acquired 65,000 shares of common stock through restricted stock units (RSUs).
- These RSUs vest in equal one-third installments annually, starting January 24, 2025.
- Shefferman also acquired stock options for 387,000 shares of common stock with an exercise price of $4.53.
- 25% of these options vest on January 24, 2026, with the remainder vesting monthly over the subsequent three years, contingent upon continuous service.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's acquisition of shares and options suggests confidence, but it's a routine transaction.
Positives
- The CEO's acquisition of shares and stock options could be interpreted as a positive signal, indicating confidence in the company's future performance.
Risks
- The vesting of the RSUs and stock options is contingent upon the CEO's continued service, creating a potential risk if the CEO were to leave the company.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedules for the RSUs and stock options extend over the next three to ten years.
Industry Context
Insider transactions are common in the pharmaceutical industry and are closely monitored by investors for signals about a company's prospects. This transaction is a routine disclosure of stock and option grants to a key executive.
Comparison to Industry Standards
- Stock option grants and RSU awards are standard compensation practices for executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
- Companies like Amgen, Gilead Sciences, and Biogen regularly grant stock options and RSUs to their executives as part of their compensation packages.
- The vesting schedules described in the document are typical, with vesting occurring over a period of several years to incentivize long-term commitment.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from the CEO.
- Employees may view the CEO's stock ownership as a positive sign for the company's future.
Key Dates
| Date | Description |
|---|---|
| 01/24/2025 | Date of transaction: Acquisition of common stock and stock options. |
| 01/24/2025 | First vesting date for RSUs, with equal one third installments on the first, second and third anniversaries of this date. |
| 01/24/2026 | First vesting date for 25% of the stock options. |
| 01/23/2035 | Expiration date of the stock options. |
| 01/28/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.